Physician profile
Jeffrey P Vanmeter
NPI 1073599262
$12,607.92
in general payments reported to CMS, 2019-2025
40 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $1,672 · 2021: $1,422 · 2022: $1,996 · 2023: $2,085 · 2024: $1,789 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,765 · Education: $63.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,764.89 |
| Education | $63.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,685.43 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $941.74 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $838.91 | 2020-2025 | Qulipta, Ubrelvy, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $785.11 | 2022-2025 | |
| Amgen INC. | $766.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $744.68 | 2019-2024 | Verquvo, Dificid, Segluromet |
| Lilly USA, LLC | $695.93 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.94 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $602.99 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $521.33 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $447.82 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $390.08 | 2024-2025 | Zenpep |
| Pfizer INC. | $363.46 | 2019-2025 | |
| Allergan, INC. | $197.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.40 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Vanmeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.